Vsee Health regains Nasdaq compliance after equity increase
DUBLIN - Goldman Sachs & Co. LLC has disclosed its trading positions in Avadel Pharmaceuticals PLC as required under Irish takeover regulations, according to a regulatory filing published Monday.
The disclosure, made under Rule 38.5(b) of the Irish Takeover Panel Act, shows Goldman Sachs held a long position of 1.77% and a short position of 0.84% in Avadel's ordinary shares as of October 24.
The filing details hundreds of individual purchase and sale transactions executed on October 24, with prices ranging between $18.53 and $18.57 per share. The largest single purchase was 4,705 shares at $18.56, while the largest sale was 9,000 shares at $18.53.
Goldman Sachs is serving as an advisor to Avadel Pharmaceuticals, according to the disclosure.
The filing also reveals swap positions, including a sold swap relating to 84 securities expiring December 17, 2025, and a purchased swap relating to 33,762 securities expiring January 20, 2026.
The disclosure was made in compliance with Irish takeover rules, which require principal traders connected to an offer or potential offer to disclose their dealings in relevant securities during the offer period.
This information was published in a Form 38.5(b) filing based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.